| Name | Title | Contact Details |
|---|
Acumen Research Group Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Care Axis is a Newcastle, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Choice Network (HCN) is a national model of a successful collaboration of community health centers (CHCs) and one of several HRSA-sponsored Health Center Controlled Networks. HCN is addressing health care disparities, providing health information technologies and strengthening the financial position of the community health care system. Founded in 1994 as a 501c(3) organization, HCN was created and is governed by its members who comprise a minority-based Board of Directors. Network members maintain their vital community orientation by retaining their local-governing, consumer-majority Boards of Directors. Community Health Centers that own and control the Network operate more efficiently, can deliver care more effectively and are working together to care for more patients.
Hematech, Inc was founded in 1998, with corporate headquarters in Sioux Falls, SD. Hematech is a subsidiary of Kyowa Hakko Kirin Company, Ltd. In 2002, Hematech and Kirin consolidated their transgenic bovine research programs in facilities in Sioux